TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00329407

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topiramate (Topamax)
Description: Medication Dosing Schedule: Days 1-3 50 mg q PM Days 4-7 50 mg BID Days 8-11 50 mg q AM \& 100 mg q PM Days 12-15 100mg BID Days 16-19 100 mg q AM \& 150 mg q PM Days 20-23 150 mg BID Days 24-27 150 mg qAM \& 200 mg q PM Days 28-70 200 mg BID Days 71-77 150 mg BID Days 78-84 100mg BID Days 85-87 50 mg BID Days 88-91 50 mg qPM
Study: NCT04982055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nadroparin (intravenous Infusion)
Description: Intravenous route of administration over a 4-hours infusion of nadroparin 3800 IU

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nadroparin (subcutaneous group)
Description: Subcutaneous route of administration of nadroparin 3800 IU
Study: NCT05225142

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified minimally invasive surgery
Description: Surgical intervention alone

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified minimally invasive surgery
Description: Surgical intervention alone

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified minimally invasive surgery
Description: Surgical intervention alone

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified minimally invasive surgery with enamel matrix derivative
Description: Surgical intervention with local application of regenerative biomaterial

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified minimally invasive surgery with enamel matrix derivative
Description: Surgical intervention with local application of regenerative biomaterial

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified minimally invasive surgery with enamel matrix derivative and bone replacement graft
Description: Surgical intervention with local application of regenerative biomaterial and bone replacement graft
Study: NCT02374645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volitinib
Description: 600mg or 800mg QD: Patients may continue to receive the treatment as long as they are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Description: 250mg QD: Patients may continue to receive the treatment as long as they are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Description: 250mg QD: Patients may continue to receive the treatment as long as they are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
Study: NCT02831166

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transradial primary percutaneous coronary intervention
Description: Transradial coronary angiography will be performed by the Judkins technique using 6 French diameter sheaths and pre-molded catheters for selective catheterization of left and right coronary arteries. Primary percutaneous coronary intervention with stent deployment will be indicated when a culprit lesion is identified, with high probability of angiographic success, being ideally performed immediately after coronary angiography Procedures will be performed according to recommendations of current guidelines. To achieve hemostasis in the transradial approach, a radial compression device will be applied, to maintain patent antegrade flow.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transfemoral primary percutaneous coronary intervention
Description: Transfemoral coronary angiography will be performed by the Judkins technique using 6 French diameter sheaths and pre-molded catheters for selective catheterization of left and right coronary arteries. Primary percutaneous coronary intervention with stent deployment will be indicated when a culprit lesion is identified, with high probability of angiographic success, being ideally performed immediately after coronary angiography Procedures will be performed according to recommendations of current guidelines. A vascular closure device will be used to achieve hemostasis in the transfemoral approach, preceded by systematic performance of femoral angiography and maintaining absolute bed rest for 60 minutes.
Study: NCT01653106

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Participate in PROMS

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Participate in PROMS

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pharmacological study
Description: Correlative studies
Study: NCT03576118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular block
Description: Deep neuromuscular block using high dose rocuronium and 8 mmHg pneumoperitoneum

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moderate neuromuscular block
Description: Moderate neuromuscular block using moderate dose rocuronium and 12-15 mmHg pneumoperitoneum
Study: NCT02718885

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Inulin
Description: Females will ingest 2 doses of 5g/inulin for a total of 10g/inulin/day for four weeks Males will ingest 2 doses of 7.5g/inulin for a total of 15g/inulin/day for four weeks
Study: NCT01911273

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will consist of Saline (0.9% w/v Sodium Chloride Injection, USP or NS)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Best Supportive Care
Description: BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life.
Study: NCT03733821

Intervention type: DEVICE
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Non-invasive brain stimulation tool
Study: NCT03143699

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immediate Feedback
Description: Students will be trained to measure blood pressure in the same way, with a brief 4-hour theoretical-practical intervention. After the training, students will measure the blood pressure of a standardized patient and observers will evaluate them using a checklist. After that, students from the intervention group will receive an immediate feedback based on the previous literature. Briefly, feedback will be based on what was directly observed and will be phrased in non-judgmental language, following the Pendleton model.
Study: NCT00566150

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levetiracetam
Description: Flexible dose up to 2500mg per day, for 6 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Flexible dose up to 2500mg per day, for 6 weeks.
Study: NCT01648855

Intervention type: OTHER
Intervention: Biological samples
Description: To measure the levels of sFlt1, angiogenic and antiangiogenic factors at birth in maternal blood, umbilical cord blood and in the amniotic fluid
Study: NCT02347189

Intervention type: DEVICE
Group type: OTHER
Intervention: Melody Transcatheter Pulmonary Valve PB1016
Study: NCT03830944

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: Assessment of complete blood count, biochemistry, inflammatory biomarkers, adhesion molecules

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: Assessment of complete blood count, biochemistry, inflammatory biomarkers, adhesion molecules

Intervention type: DIAGNOSTIC_TEST
Intervention: transthoracic echocardiography
Description: Assessment of the ventricular anatomy, size, function, speckle tracking, myocardial strain, valvular function.

Intervention type: DIAGNOSTIC_TEST
Intervention: transthoracic echocardiography
Description: Assessment of the ventricular anatomy, size, function, speckle tracking, myocardial strain, valvular function.

Intervention type: DIAGNOSTIC_TEST
Intervention: Late Gadolinium-Enhancement Cardiac Magnetic Resonance
Description: Assessment of the ventricular anatomy, function, viability, degree of fibrosis, quantification of infarct size, mass.

Intervention type: DIAGNOSTIC_TEST
Intervention: Late Gadolinium-Enhancement Cardiac Magnetic Resonance
Description: Assessment of the ventricular anatomy, function, viability, degree of fibrosis, quantification of infarct size, mass.

Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary Angio Computed Tomography
Description: Assessment of coronary plaque anatomy, morphology, vulnerability features, quantification of epicardial adipose tissue

Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary Angio Computed Tomography
Description: Assessment of coronary plaque anatomy, morphology, vulnerability features, quantification of epicardial adipose tissue
Study: NCT02718885

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Maltodextrin
Description: Females will ingest 2 doses of 5g/maltodextrin for a total of 10g/maltodextrin/day for four weeks Males will ingest 2 doses of 7.5g/maltodextrin for a total of 15g/maltodextrin/day for four weeks
Study: NCT03122860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM04690
Description: Healthcare professional-administered intra-articular injection performed once on Day 1 of the study
Study: NCT03797300

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spry Loop Band
Description: Loop band measures pulse oximetry and respiration rate
Study: NCT02300181

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03122860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM04690
Description: Healthcare professional-administered intra-articular injection performed once on Day 1 of the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM04690
Description: Healthcare professional-administered intra-articular injection performed once on Day 1 of the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM04690
Description: Healthcare professional-administered intra-articular injection performed once on Day 1 of the study

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Healthcare professional-administered intra-articular injection performed once on Day 1 of the study
Study: NCT02300181

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bacillus subtilis var natto DC-15
Study: NCT03460912

Intervention type: DEVICE
Intervention: Bipolar and monopolar probes (SPESS MEDICA S.r.l. Via Buccari 16153 Genova (GE), Italy) administered to all participants.
Description: Bipolar and monopolar probes (SPESS MEDICA S.r.l. Via Buccari 16153 Genova (GE), Italy) administered to all participants.They compared each others(bipolar vs monopolar) via amplitudes and latency values.
Study: NCT04246632

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CapsoCam Colon Capsule Endoscopy
Description: CapsoCam® Colon is intended to provide visualization of the colon and the detection of colon polyps in adults.
Study: NCT04725487

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard integration program with social and health promoting intervention
Description: * Basic language course, internships, courses in Labour market knowledge and Danish culture~* Physical activity workshops~* Community gardening (garden workshops)~* Entrepreneurship course~* MindSpring course~* Family excursions~* Danish language workshops

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard integration program
Description: Standard integration program (basic language course, internships, courses in Labour market knowledge and Danish culture)
Study: NCT03122860

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Healthcare professional-administered intra-articular injection performed once on Day 1 of the study
Study: NCT01078168

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acitretin
Description: 30mg per day from Day 1 to Day 28

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01875731

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BPS
Description: In this study a strategy based on BPS guided antibiotic use in children with community acquired pneumonia implementation will be compared with enforced guideline.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Guideline
Description: Strategy based on enforced guideline guided antibiotic use
Study: NCT02400268

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 7 days course of antibiotic treatment
Description: Standard antibiotic treatment approved for enterobacteraciae infections
Study: NCT03330470

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: participants will be subjected to 3 months supervised exercise intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: participants will be subjected to 3 months supervised exercise intervention

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: carnosine supplementation
Description: participants will be instructed to take carnosine 2 times daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: carnosine supplementation
Description: participants will be instructed to take carnosine 2 times daily

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: stretching
Description: participants will be subjected to 3 months supervised stretching program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: stretching
Description: participants will be subjected to 3 months supervised stretching program

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: supplementation with placebo
Description: participants will be instructed to take placebo 2 times daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: supplementation with placebo
Description: participants will be instructed to take placebo 2 times daily
Study: NCT03287427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TetMYB Vaccine
Description: Weekly intra-dermal injections of either 0.1mg, 0.5mg or 1.0mg on day 1 for week 1 to week 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-A317
Description: 3 weekly IV injections of 200mg commencing from Week 4.
Study: NCT02217917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivipansel
Description: Rivipansel administered as a single dose subcutaneously with rHuPH20 in cross-over fashion. Each subject may receive up to 4 study treatments (placebo and up to 3 doses of rivipansel). The planned dose levels are 350 mg, 1210 mg, and 4200 mg (these are subject to change based on emerging data).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matched Placebo administered as single dose subcutaneously with rHuPH20.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivipansel
Description: Rivipansel administered q12h for 7 days (a total of 13 doses) subcutaneously with rHuPH20. Planned doses are 1400 mg loading and 700 mg maintenance for 12 doses (these are subject to change based on emerging data).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivipansel
Description: Rivipansel administered q12h for 7 days (a total of 13 doses) subcutaneously with rHuPH20. Planned doses are 2800 mg loading and 1400 mg maintenance for 12 doses (these are subject to change based on emerging data).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matched Placebo administered q12h for 7 days (a total of 13 doses) subcutaneously with rHuPH20.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matched Placebo administered q12h for 7 days (a total of 13 doses) subcutaneously with rHuPH20.
Study: NCT01940081

Intervention type: OTHER
Intervention: Transthoracic echocardiography

Intervention type: OTHER
Intervention: Transthoracic echocardiography

Intervention type: OTHER
Intervention: Transthoracic echocardiography

Intervention type: OTHER
Intervention: Exercise test

Intervention type: OTHER
Intervention: Exercise test

Intervention type: OTHER
Intervention: Exercise test

Intervention type: OTHER
Intervention: 24-hour Holter electrocardiogram

Intervention type: OTHER
Intervention: 24-hour Holter electrocardiogram

Intervention type: OTHER
Intervention: 24-hour Holter electrocardiogram

Intervention type: OTHER
Intervention: Contrast-enhanced magnetic resonance imaging

Intervention type: OTHER
Intervention: Contrast-enhanced magnetic resonance imaging

Intervention type: OTHER
Intervention: Contrast-enhanced magnetic resonance imaging

Intervention type: OTHER
Intervention: 123-iodine metaiodobenzylguanidine imaging

Intervention type: OTHER
Intervention: 123-iodine metaiodobenzylguanidine imaging

Intervention type: OTHER
Intervention: Blood samples

Intervention type: OTHER
Intervention: Blood samples

Intervention type: OTHER
Intervention: Blood samples

Intervention type: GENETIC
Intervention: Genetic analysis

Intervention type: GENETIC
Intervention: Genetic analysis

Intervention type: PROCEDURE
Intervention: Invasive electrophysiological study

Intervention type: PROCEDURE
Intervention: Invasive electrophysiological study

Intervention type: PROCEDURE
Intervention: Endomyocardial biopsy

Intervention type: PROCEDURE
Intervention: Intraoperative biopsy

Intervention type: PROCEDURE
Intervention: Intraoperative biopsy

Intervention type: PROCEDURE
Intervention: Intraoperative mapping and/or ablation
Study: NCT04411745

Intervention type: OTHER
Intervention: No intervention, observational study
Study: NCT02126839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol MDPI
Description: 90 mcg/actuation of the multidose dry powder inhaler (MDPI).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo delivered via a multidose dry powder inhaler (MDPI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ProAir HFA inhaler
Description: Rescue medication, ProAir hydrofluoroalkane (HFA) inhaler, was dispensed at the run-in visit for the relief of asthma symptoms to be administered as needed.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ProAir HFA inhaler
Description: Rescue medication, ProAir hydrofluoroalkane (HFA) inhaler, was dispensed at the run-in visit for the relief of asthma symptoms to be administered as needed.
Study: NCT00172042

Intervention type: DRUG
Group type: OTHER
Intervention: Zoledronic acid 4 mg
Description: Zoledronic acid 4 mg in 5 mL concentrated solution prepared with 100 mL calcium free infusion solution (0.9 % sodium chloride or 5% glucose solution).
Study: NCT01471379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milnacipran
Description: 50mg Milnacipran PO, BID, for 6 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Milnacipran
Description: 50mg Milnacipran PO, BID, for 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milnacipran
Description: Milnacipran, 100mg PO, BID, for six weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Milnacipran
Description: Milnacipran, 50mg PO BID for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive pill, identical in shape, size, and appearance to active drug, PO, BID.
Study: NCT05537077

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prolotherapy
Description: DPT was applied as a total of 3 sessions at 0, 3 and 6 weeks. In each session, intra-articular 5 ml and periarticular 10 ml dextrose injections were administered to the knee. Periarticular injection was applied to 10 points as 1 ml in each region. The regions were determined as medial and lateral coronary ligaments, proximal and distal medial and lateral collateral ligaments, pes anserinus region, proximal and distal patellar tendon, quadriceps tendon attachment area.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prolotherapy
Description: DPT was applied as a total of 3 sessions at 0, 3 and 6 weeks. In each session, intra-articular 5 ml and periarticular 10 ml dextrose injections were administered to the knee. Periarticular injection was applied to 10 points as 1 ml in each region. The regions were determined as medial and lateral coronary ligaments, proximal and distal medial and lateral collateral ligaments, pes anserinus region, proximal and distal patellar tendon, quadriceps tendon attachment area.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prolotherapy
Description: DPT was applied as a total of 3 sessions at 0, 3 and 6 weeks. In each session, intra-articular 5 ml and periarticular 10 ml dextrose injections were administered to the knee. Periarticular injection was applied to 10 points as 1 ml in each region. The regions were determined as medial and lateral coronary ligaments, proximal and distal medial and lateral collateral ligaments, pes anserinus region, proximal and distal patellar tendon, quadriceps tendon attachment area.
Study: NCT00172042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid 4 mg
Description: Zoledronic acid 4 mg in 5 mL concentrated solution prepared with 100 mL calcium free infusion solution (0.9 % sodium chloride or 5% glucose solution).
Study: NCT05537077

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home based exercise program
Description: Knee ROM, isometric and isotonic quadriceps strengthening exercises were given as 2 sets of 10 repetitions per day for 12 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home based exercise program
Description: Knee ROM, isometric and isotonic quadriceps strengthening exercises were given as 2 sets of 10 repetitions per day for 12 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home based exercise program
Description: Knee ROM, isometric and isotonic quadriceps strengthening exercises were given as 2 sets of 10 repetitions per day for 12 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home based exercise program
Description: Knee ROM, isometric and isotonic quadriceps strengthening exercises were given as 2 sets of 10 repetitions per day for 12 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hotpack therapy
Description: Hotpack treatment was applied for 20 minutes at 0, 3 and 6 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hotpack therapy
Description: Hotpack treatment was applied for 20 minutes at 0, 3 and 6 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hotpack therapy
Description: Hotpack treatment was applied for 20 minutes at 0, 3 and 6 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hotpack therapy
Description: Hotpack treatment was applied for 20 minutes at 0, 3 and 6 weeks.